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ABCC6 Expression Is Regulated by CCAAT/Enhancer-
Binding Protein Activating a Primate-Specific
Sequence Located in the First Intron of the Gene
Marcin Ratajewski1,5, Hugues de Boussac2,5, Iwona Sachrajda1, Caroline Bacquet2, Tu¨nde Kova´cs3,4,
Andra´s Va´radi2, Lukasz Pulaski1 and Tama´s Ara´nyi2
Pseudoxanthoma elasticum (PXE), a rare recessive genetic disease causing skin, eye, and cardiovascular lesions,
is characterized by the calcification of elastic fibers. The disorder is due to loss-of-function mutations of the
ABCC6 gene, but the pathophysiology of the disease is still not understood. Here we investigated the
transcriptional regulation of the gene, using DNase I hypersensitivity assay followed by luciferase reporter gene
assay. We identified three DNase I hypersensitive sites (HSs) specific to cell lines expressing ABCC6. These HSs
are located in the proximal promoter and in the first intron of the gene. We further characterized the role of the
HSs by luciferase assay and demonstrated the transcriptional activity of the intronic HS. We identified the
CCAAT/enhancer-binding protein b (C/EBPb) as a factor binding the second intronic HS by chromatin
immunoprecipitation and corroborated this finding by luciferase assays. We also showed that C/EBPb interacts
with the proximal promoter of the gene. We propose that C/EBPb forms a complex with other regulatory
proteins including the previously identified regulatory factor hepatocyte nuclear factor 4a (HNF4a). This
complex would account for the tissue-specific expression of the gene and might serve as a metabolic sensor.
Our results point toward a better understanding of the physiological role of ABCC6.
Journal of Investigative Dermatology (2012) 132, 2709–2717; doi:10.1038/jid.2012.218; published online 5 July 2012
INTRODUCTION
Pseudoxanthoma elasticum (PXE, Online Mendelian Inheritance
in Man (OMIM) 264800) is a rare Mendelian disorder
characterized by calcification and fragmentation of the elastic
fibers (Li et al., 2009b; Uitto et al., 2010; Varadi et al., 2011).
Patients in their first decades of life develop yellowish papules at
the neck and flector areas of the body. Plaques of papular lesions
and redundant skin may appear during the slowly progressing
disease in the axillae, the inguinal regions, and the periumbilical
area. The skin looses its elasticity and can become wrinkled.
Ultrastructural analyses of the dermis show the fragmentation of
the elastic fibers and the accumulation of calcium deposits,
which can be visualized by von Kossa staining. Fragmentation of
the elastic fibers of the Bruch’s membrane in the eye may lead to
neovascularization and potentially severe loss of vision. In
parallel, cardiovascular complications and coronary artery
disease may complete the syndrome.
Recessive mutations in the ABCC6 ATP-binding cassette
transporter gene lead to the development of the disease
(Bergen et al., 2000; Le Saux et al., 2000; Ringpfeil et al.,
2000). The mutation detection rate is over 90% (Vanakker
et al., 2008), with more than 300 mutations reported and
compiled in the ABCC6 mutation database. Stop codon
mutation p.R1141X represents 25% of all observed muta-
tions. It should be noted that PXE is also associated with a
promoter polymorphism of the gene, and other rare cases of
promoter mutations exist as well (Schulz et al., 2006; Hendig
et al., 2008). The biochemically well-characterized ABCC6
gene product is a plasma membrane protein transporting a
currently unknown molecule to the bloodstream (Ilias et al.,
2002). Surprisingly, the gene has a very restricted tissue-
specific expression pattern, as it is expressed predominantly
in the liver and is absent from the tissues affected by the
disease (Matsuzaki et al., 2005). Skin transplantation experi-
ments between wild-type and knockout mice and the
development of parabiotic animals confirmed the role of this
expression pattern by showing that the disease should be
considered metabolic (Jiang et al., 2009, 2010; Uitto et al.,
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2010). Recent data on acquired PXE after liver transplantation
in human patients (Bercovitch et al., 2011) also corroborate
the idea that PXE is a metabolic disorder caused either by the
absence of a molecule from the serum secreted by the
hepatocytes or the presence of a molecule, which is normally
not present (Le Saux et al., 2006).
Several other pathologies are also associated with the PXE
phenotype. Although PXE is an autosomal recessive disorder
and carriers of one loss-of-function mutant ABCC6 allele
have no obvious clinical phenotype, they probably have an
increased risk to develop coronary artery disease (Trip et al.,
2002; Koblos et al., 2010). Furthermore, when they are
carriers of other mutations as well, e.g., in the GGCX gene,
PXE-like phenotype can develop (Li et al., 2009a). A
significant portion (B5%) of b-thalassemic patients develop
PXE-like phenotype (Hamlin et al., 2003; Aessopos et al.,
2008) most probably due to the downregulation of ABCC6
without any mutation in the gene (Martin et al., 2011).
Although several studies have been conducted to under-
stand the transcriptional regulation of the gene (Aranyi et al.,
2005; Jiang et al., 2006; de Boussac et al., 2010; and Varadi
et al., 2011 and references therein), to date, only the essential
role of hepatocyte nuclear factor 4a (HNF4a) is known in the
tissue-specific expression of the gene from our work as well
as the work of others (Douet et al., 2006; Bolotin et al., 2010;
de Boussac et al., 2010). We have also shown the regulatory
role of the extracellular signal–regulated kinase 1 and 2,
which exerts its negative action on the expression of the gene
via the inhibition of HNF4a (de Boussac et al., 2010). The
role of DNA methylation and several other minor factors has
been uncovered; however, the mechanisms of relatively high
expression levels of the gene in hepatocytes remained poorly
understood (Varadi et al., 2011 and references therein). In
light of future potential allele-specific therapy of PXE (Le Saux
et al., 2011), improvement of PXE-related phenotypes, and in
order to decrease the ABCC6 haploinsufficiency associated
cardiovascular risks, we aimed to identify crucial missing
factors in the transcriptional regulation of the human ABCC6
gene. We therefore searched for further regulatory sequences
and identified a primate-specific activator element in the first
intron of ABCC6 with strong activity in the human hepatoma
HepG2 and the differentiated colon carcinoma Caco-2 cells.
We also demonstrated that the activator interacts with the
proximal promoter and binds CCAAT/enhancer-binding
protein b (C/EBPb) and probably other currently unidentified
factors.
RESULTS
Expression of the ABCC6 gene in model cell lines
To investigate the transcriptional regulation of the ABCC6
gene, we first chose model cell lines. We selected two cell
lines characterized by high and two by low expression level
of the gene. From our previous studies, we already knew that
HepG2 cells have a high expression level (Aranyi et al.,
2005); HEK293 and HeLa cells have very low expression
levels or do not express the gene (Aranyi et al., 2005; de
Boussac et al., 2010). Previous data showed that Abcc6 has a
relatively high expression level in rodent small intestine
(Maher et al., 2005, 2006). Indeed, we previously observed
an intermediate expression level in Caco-2 cells (Aranyi
et al., 2005). These cells are known to spontaneously
differentiate to intestinal epithelial-like cells in postconfluent
culture (Grasset et al., 1984). We now performed sponta-
neous differentiation experiments with Caco-2 cells. As a
control, we confirmed the increased expression of some
differentiation markers (Gelebart et al., 2002; Ribiczey et al.,
2007). The expression level changes of several ABC transporter
genes were also analyzed. Although ABCC1 levels progres-
sively decreased, ABCC2, ABCC3, and ABCG5 expression
levels increased in parallel with that of ABCC6 (not shown).
Indeed, after the cells reached 50% confluency, the expression
level of ABCC6 consistently increased until postconfluent day 6
and became similar to that observed in HepG2 cells. These
data confirmed that Caco-2 cells can be used as a model
system in our study for high expression level of ABCC6.
DNase I assay revealed an active genomic region
To identify regulatory sequences of the ABCC6 gene, we
performed DNase I hypersensitivity assay (DHA) (Lu and
Richardson, 2004). The partial digestion of the genomic DNA
in its nuclear context by DNase I reveals transcriptionally
active regions because of their increased sensitivity to the
enzyme. The great advantage of this technique is that it maps
physiologically relevant regulatory sequences in a hypoth-
esis-free manner, i.e., without any prior analysis of the region.
We investigated the first intron of the ABCC6 gene and a 10-
kb upstream region between ABCC6 and NOMO3, the
neighboring gene (Figure 1a). We mapped the hypersensitive
sites (HSs) of this region by Southern blot analysis. We
designed the ABCC6-specific probe to recognize the 30 end of
the first intron of the gene. This location allows the screening
for potential HSs in the ABCC6 regulatory sequences with
high accuracy (Figure 1a).
After performing DHA in HepG2 cells, three HSs were
revealed in the studied region (Figure 1b). We identified the
11-kb fragment as a product of enzymatic digestion at a HS in
the first intron of NOMO3 gene. The two other fragments of
2.2 and 1.8 kb revealed HSs close to the transcription start
site of the ABCC6 gene. We decided to further study only the
two HSs close to the transcription start site of the ABCC6
gene, as no data indicate that the HSs in the NOMO3 gene
have any role in the regulation of ABCC6.
The two closer HSs were thus further investigated by the
analysis of a 4.7-kb DNA fragment containing the first intron
and the proximal promoter of ABCC6. DHA analyzed by this
higher-resolution Southern blot showed that the two HSs
previously identified around the transcription start site of
ABCC6 were in fact three different HSs, represented in the
Southern blot now by bands at 2.2, 1.7, and 1.3 kb. We
named these HS sites from 50 to 30, HS1 to HS3 (Figure 1c).
Both the DNase I digestion and our Southern blot
conditions have a resolution of B150 bp; thus, we located
HS1 in the proximal promoter of the ABCC6 gene between
200 and 50 bp, whereas both HS2 and HS3 are situated in
the first intron of ABCC6 between þ 310 and þ 460bp and
between þ600 and þ 750bp, respectively (Figure 1c).
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HSs are cell-type specific
As ABCC6 has tissue-specific expression, we next asked
whether the HS observed in HepG2 are also cell-type
specific. To answer this question, we performed DHA on
Caco-2, HEK, and HeLa cells (Figure 1d and e). Caco-2 cells
were B95% confluent. We observed HS1 in the 4.7-kb
genomic DNA fragment studied as earlier in the HepG2 cells.
However, we obtained only very weak signals for HS2 and
HS3; therefore, we could not confirm undoubtedly the
presence of these sites in Caco-2 cells.
In contrast, when we performed DHA in HEK and HeLa
cells, we did not observe any HS in the same region.
Indeed, HS1, HS2, and HS3 observed previously were
absent from HEK and HeLa cells when we analyzed the
larger 15.7-kb fragment. The entire region seemed to have a
much more compact chromatin structure, as the HS in the
first intron of NOMO3 appeared only upon using higher
DNase I concentrations in the assay. The detection of
this HS also served as a positive control for the experiment
(Figure 1e), demonstrating the cell-type specificity of
HS1–3.
Functional characterization of the HSs in the proximal
promoter and the first intron
In the following experiments, we investigated the function-
ality of the different HSs, and more specifically we focused
on the two intronic HSs by luciferase assay. We assumed
from the localization of HS1 in the proximal promoter
that it marks the binding of HNF4a (de Boussac et al., 2010
and references therein). We mapped by luciferase
assay the different HSs with constructs starting at 332
(relative to the translation start site) and giving maximal
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Figure 1. DNase I hypersensitivity assay identifies cell type–specific hypersensitive sites (HSs). (a) Map of the NOMO3–ABCC6 intergenic region. (b) Detection
of HS in HepG2 cells. (c) Higher-resolution analysis. (d) Detection of HS in Caco-2 cells (95% confluency). (e) Detection of HS in HeLa and HEK293 cells.
Please note that the nonspecific (‘‘NS’’) band on e does not respect the borders of the loaded lanes. Arrows indicate HS; ‘‘M’’ is a 1-kb marker (numbers indicate
fragment sizes in kb). HSs are indicated by ‘‘X’’ on the schematic genomic map. DNase I partial digestion was carried out for 3minutes with 0, 9, 11, 13, 15, and
17mg (HepG2); 0, 5, 10, 15, and 20mg (Caco-2); and 0, 15, 20, 25, and 30 mg (HeLa and HEK293) enzyme.
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promoter activation (Aranyi et al., 2005). The constructs
were progressively truncated at the 30 end from þ960
(Figure 2a).
In HeLa and HEK cells, we saw a low basal activity of the
332/þ 72 and 332/þ513 constructs, which corresponds
to the activation caused by the 145/þ72 region observed in
every cell type tested so far, as reported in our previous
studies (Aranyi et al., 2005; de Boussac et al., 2010). The
addition of the þ 514/þ629 fragment to the 332/þ513
construct led to the doubling of the reporter gene activity,
which was not further increased by the addition of further
intronic fragments (Figure 2a).
Surprisingly, in HepG2 and Caco-2 cells, the activity of
332/þ 960 was B6–8 times higher than the activity of the
proximal promoter 332/þ 72. This activation remained at
the same level when the construct was truncated at þ688
but dropped to the level of the activity of the proximal
promoter when the construct was truncated at þ 629 (Figure
2a). When we tried to further narrow down the response
element, an intermediate activity was observed for the
construct 332/þ 652 relative to the constructs 332/
þ 629 and 332/þ 688 in both HepG2 and Caco-2 cells
(Figure 2b). In our following experiments, we have also
shown that the 60-bp intronic sequence has no enhancer
activity in plasmids specifically designed for testing this (not
shown). Altogether, our data suggest the presence of at least
one strong cell type–specific activator element in the first
intron of the ABCC6 gene between þ629 and þ688bp,
which overlaps with HS3.
Identification of primate-specific regulatory elements in the
ABCC6 gene
Seeing the major role in the regulation of ABCC6 of the
sequence overlapping with HS3, we next wanted to identify
the regulatory proteins binding the HS3 region. Therefore, we
performed in silico analysis of the 60-bp intronic segment.
First, we investigated the evolutionary conservation of the
region (Supplementary Figure S1A online). The þ 629/þ652
fragment of the human gene was completely absent from the
majority of investigated species, except for primates and
small conservation in the rabbit and the African elephant. The
þ 653/þ688 region remained completely absent from
mouse, rat, and chicken, whereas it was present, in addition
to primates, in the African elephant andB50% conserved in
guinea pig, cow, and rabbit. The ABCC6 proximal promoter
was also investigated by the same bioinformatic approach,
which demonstrated the presence of another primate-specific
sequence while efficiently identifying the HNF4a-binding site
in almost all analyzed species (Supplementary Figure S1B
online).
C/EBPb activates ABCC6 expression via HS3
Next, we investigated the human sequence for the presence
of transcription factor–binding sites in the 60-bp-long intronic
region. The search engines indicated only few sites. Interest-
ingly, some of the factors binding the putative sites are
enriched in the liver (C/EBPb, HNF3).
We tested the potential role of the transcription factors
identified by coexpressing them with our 332/þ688
construct and HNF4a in HeLa cells. We coexpressed HNF4a,
as we hypothesized that its presence might be necessary for
the activity of the factor(s) binding the putative intronic
response element(s). The only transcription factor that
induced the expression of our construct after the coexpres-
sion with HNF4a was C/EBPb (Figure 2c).
Next, we wished to show the binding of C/EBPb to the
ABCC6 intronic activator in the chromatin environment of
HepG2 cells, where the gene is endogenously expressed.
Therefore, we performed chromatin immunoprecipitation
assay with an anti-C/EBPb antibody. We observed a more
than 3-fold enrichment of the target region (þ503/þ 700) in
the immunoprecipitated fraction, demonstrating thereby
the binding of C/EBPb to the first intron of the human
ABCC6 gene in the chromatin context in HepG2 cells
(Figure 2d). Altogether, these data prove a major role for
C/EBPb in the transcriptional regulation of the human
ABCC6 gene.
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Figure 2. Hypersensitive site 3 (HS3) overlaps with a primate-specific
intronic activator sequence, which binds CCAAT/enhancer-binding protein b
(C/EBPb). Results of luciferase assays were standardized and expressed as fold
induction of the empty pGL3-basic vector, mean±SEM (n¼5). (a)
Transcriptional activity of the first intron of ABCC6. The genomic map
indicates the HS by ‘‘X.’’ (b) Further mapping of the þ 629/þ 688 region. (c)
Putative transcription factors binding the 60-bp sequence were tested in HeLa
cells by luciferase assay in coexpression experiment with the 332/þ 688
construct and a vector containing hepatocyte nuclear factor 4a (HNF4a).
Factors tested were as follows: 1: USF2; 2: RELA; 3: HNF3b; 4: ELK1; 5:
C/EBPb. HNF4a overexpression is indicated by þ and empty vector is
indicated by . (d) Chromatin immunoprecipitation (ChIP) of C/EBPb in
HepG2 cells. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and IgG
were used as controls.
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Interplay between the proximal promoter and the first intron
In our following experiment, we mapped the region
responsible for the binding of C/EBPb, as the resolution of
the chromatin immunoprecipitation (ChIP) is not sufficient to
locate exactly the response element. Different luciferase
constructs were expressed alone or in the presence of C/EBPb
or HNF4a or both in HeLa cells. We found in these
experiments at least two C/EBPb-binding sites between
þ 513/þ629 and þ630/þ 652 (Figure 3a).
In these experiments, we have also observed that the
overexpression of C/EBPb alone can reach a similar pattern of
induction of the constructs than in the presence of HNF4a,
which is therefore not an obligatory partner of C/EBPb in
this experimental context (Figure 3a). Nevertheless, these
experiments also suggested an interplay between the
proximal promoter and the intronic region as concluded by
the comparison of luciferase activities of constructs 145/
þ 688 and 332/þ688. We further explored the possible
interactions between the proximal promoter of ABCC6 and
the intronic HSs in HepG2 and Caco-2 cells (Figure 3b) by
testing new constructs. The new 234/þ 688 and 209/
þ 688 constructs were compared with the previously
described 332/þ688 construct. The 332/þ 688 and
234/þ 688 constructs showed similarly high luciferase
activities (Figures 3b). According to our observations in HeLa
cells, and in contrast to the longer constructs, the 209/
þ 688 construct showed a low luciferase activity, confirming
that the intronic activator sequence is interacting with the
234/209 fragment and not with the 165/145 sequence,
which binds HNF4a (de Boussac et al., 2010). Interestingly,
the 234/209 fragment corresponds to the primate-specific
sequence identified in the proximal promoter (Supplementary
Figure S1B online).
In our final set of experiments, we performed luciferase
assays in HepG2, Caco-2, and HeLa cells with constructs
harboring mutations at the predicted C/EBPb-binding sites to
determine the major site of action of the protein (Figure 3c
and d). Although the mutagenesis of site 1 (þ539/þ547) had
only a small effect, the mutagenesis of site 2 (þ 585/þ594)
increased the activity of the construct in HeLa cells when
coexpressed with C/EBPb (Figure 3c). Therefore, the role of
the second site could not be evaluated. Interestingly, the
mutagenesis of the third site, the most active site located
between þ 632 and þ 640, abolished completely the
activation of site 3 by C/EBPb in HeLa cells (Po0.01).
Indeed, the activity of the construct mut3(332/þ688) in the
presence of C/EBPb was not different from that of the
construct truncated at þ629 (see Figure 3a). Double
mutation of sites 1 and 3 had similar effect as the single
mutation of site 3, whereas the triple mutation of the sites had
a smaller effect due to the adverse behavior of the mutation at
site 2. Deletion of the HS2 region had no significant effect.
Similar behavior of the mutant constructs was observed in
HepG2 and Caco-2 cells (Figure 3d). However, it should be
noted that constructs with mutations at site 3 expressed in
HepG2 and Caco-2 still maintained a higher residual activity
of the region than expected. This demonstrates that the
þ 630/þ652 sequence binds specifically C/EBPb and
suggests that additional endogenous activator factor(s) bind(s)
the þ652/þ 688 fragment (Figure 3d and not shown).
DISCUSSION
ABCC6 is characterized by a strict tissue-specific expression
overlapping with the expression pattern of the HNF4a
transcription factor (Sladek et al., 1990; Matsuzaki et al.,
2005). However, HNF4a and the other previously identified
factors seemed to have only a small transcriptional activator
potential in the regulation of ABCC6, suggesting that other
elements are also required, as the expression level of the gene
is relatively high in hepatocytes. In this study, we have
demonstrated that the human ABCC6 gene is under the
control of a strong cell type–specific activator located in the
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Figure 3. Characterization of CCAAT/enhancer-binding protein b (C/EBPb)
binding to the intronic activator region. Results of luciferase assays were
standardized as in Figure 2. (a) Mapping of C/EBPb-binding site. Luciferase
constructs were coexpressed with hepatocyte nuclear factor 4a (HNF4a) or C/
EBPb or both or none in HeLa cells. (b) Interaction of the C/EBPb-binding
region and the promoter in HepG2 and Caco-2 cells. ABCC6 luciferase
constructs were tested in (c) HeLa cells overexpressing C/EBPb and in (d)
HepG2 and Caco-2 cells. The following constructs were tested: 1: pGL3; 2:
ABCC6 (332/þ688); 3: ABCC6mut1 (332/þ688); 4: ABCC6mut2 (332/
þ688); 5: ABCC6mut3 (332/þ688); 6: ABCC6mut1,3 (332/þ 688); 7:
ABCC6mut1,2,3 (332/þ 688); and 8: ABCC6delHS2 (332/þ 72 þ 629/
þ688). Constructs are described in Materials and Methods. Asterisks indicate
significant effect relative to wild type. (e) The scheme summarizes a working
model for the transcriptional regulation of ABCC6. ERK1/2, extracellular
signal–regulated kinases 1 and 2; HBP 1 and 2, hypothetical binding proteins
1 and 2; HS, hypersensitive site.
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first intron of the gene. We also showed that this sequence
specifically binds C/EBPb and at least one further activator
protein. Finally, we have shown that to develop its full activity
C/EBPb requires the interaction with the proximal promoter of
the gene. Our results are summarized in Figure 3e.
We investigated model cell lines in which ABCC6 is
expressed (HepG2 and Caco-2) or is not expressed (HeLa and
HEK), to identify further response elements and factors
playing an important role in the regulation of the gene. We
used DHA followed by luciferase reporter gene assay. It
should be noted that the genome contains two human-
specific ABCC6 pseudogenes, as a result of evolutionarily
recent segmental duplications (Pulkkinen et al., 2001;
Symmons et al., 2008). Because of the 99% sequence identity
of the three loci, it was impossible to perform an ABCC6-
specific DHA, i.e., the observed HS may reflect any of the
three genomic loci. Nevertheless, we considered that as both
pseudogenes are expressed (Pulkkinen et al., 2001; Aranyi
et al., 2005) and are located within large, almost identical
duplicated genomic regions, the same HS pattern might
characterize all three loci. However, in the following
luciferase reporter gene experiments, which were performed
to study the functional role of the HSs, the plasmid constructs
contained the ABCC6-specific sequence.
The approach proved to be efficient, and cell type–specific
activator elements (HS2 and HS3) were found in the first
intron of the gene similar to CFTR, another member of the
ABCC gene family (Smith et al., 1996). The physiologic role
of HS3 was in the focus of this study. Interestingly, this strong
activator sequence turned out to be primate specific as
observed when aligned with other ABCC6 sequences from
different species (Supplementary Figure S1A online).
Our bioinformatic analysis predicted the binding of
different transcription factors to the 60-bp-long intronic
region of the human gene characterized by increased
transcriptional activity. In our experiments, only C/EBPb
was found to specifically bind and transactivate the
sequence. We showed the specific binding of the protein
by several methods. ChIP assays demonstrated the binding of
C/EBPb to at least one functional site between þ200 bp and
þ 1 kb considering the resolution of our technique (Figure
2d). We have extensively mapped the binding of C/EBPb in
the first intron of ABCC6 by luciferase reporter gene assays as
well (Figures 2c and 3): (1) at least two binding sites exist
between þ 513 and þ688, conferring a 5–6-fold activation
to the reporter constructs, as shown by coexpression of
C/EBPb and HNF4a with wild-type constructs; (2) as shown
by the study of mutant constructs, the major site is located at
þ 632/þ640, which overlaps with the 50 end of a 60-bp
region of HS3 (Figure 3c and d).
We have also demonstrated that the intronic activator
region overlapping with HS3 interacts with HS1 located in
the proximal promoter (Figure 3b). We have found that
C/EBPb (HS3 region) has to interact with the proteins binding
the 332/145 (HS1) region to elicit its full activity. This
latter sequence binds HNF4a and also harbors the 234/
209 sequence, the site for the second important cell
type–specific activator of the proximal promoter, needing
HNF4a for its binding according to our previous data
(Ratajewski et al., 2009).
In this study, we have shown that the activation of the
intronic sequence by C/EBPb needs the presence of the 234/
209 sequence (Figure 3a and b). We hypothesize that, in
HeLa cells, when C/EBPb was overexpressed, a protein
complex formed including C/EBPb and the protein binding
the 234/209 sequence even in the absence of HNF4a
(Figure 3a, comparison of constructs 332/þ 688 and 145/
þ 688 coexpressed with C/EBPb). We therefore consider that
in these cells the primary interaction is between C/EBPb and
the factor binding the 234/209 sequence. This result also
suggests that this hypothetical binding protein (HBP1), which
is present in the cells, is unable to fully activate the construct
in the absence of C/EBPb (Figure 3e). Although we
considered previously that the activator that binds the
234/209 sequence is a tissue-specific factor, this observa-
tion also suggests that HBP1 might be more widely expressed
than previously thought (Ratajewski et al., 2009). As our
previous data indicated the dependence of HBP1 binding on
HNF4a binding, we hypothesize that in HepG2 and Caco-2
cells, which reflect much better the physiological regulation
of ABCC6 than HeLa cells, a complex composed of HNF4a,
C/EBPb, and HBP1 is playing the major regulatory role in the
expression of the gene. Detailed luciferase analyses also
showed that the 332/þ652 construct had an intermediate
activity compared with the 332/þ 688 and 332/þ629
luciferase reporter gene constructs in both HepG2 and Caco-
2 cells (Figure 2b). Our data clearly indicate that C/EBPb is
the main activator of the þ 630/þ652 region, whereas
another hypothetical binding protein (HBP2) also binds the
þ 652/þ688 region. Most probably, HBP2 is also included
in the complex, as in the absence of 332/145 region the
entire þ 630/þ688 region loses its transcriptional activator
potential (Figure 3b and e).
Interestingly, and in agreement with our findings on the
intronic segment, the 234/209 sequence containing the
binding site for HBP1 is not conserved evolutionarily
according to our in silico analysis (Supplementary Figure S1
online), suggesting that the highlighted regulatory network is
entirely primate specific. This strongly suggests that the
rodent Abcc6 genes are not appropriate models of the
transcriptional regulation of the human gene.
C/EBPb is a member of the CCAAT/enhancer-binding
protein family (Akira et al., 1990). These transcription factors
have a basic leucin zipper domain and bind DNA as
homodimers or heterodimerize with another member of the
family and recognize very similar or identical sequences
(Okazaki et al., 2002; Ramji and Foka, 2002). In hepatocytes,
two C/EBPs, a and b, are highly expressed. Our data therefore
do not exclude the potential role of C/EBPa or other C/EBPs in
the transcriptional regulation of ABCC6 in addition to that of
C/EBPb. Interestingly, both C/EBPa and b typically activate
the transcription of genes that play a role in metabolism by
binding their enhancer (Ramji and Foka, 2002). They often
act in concert with HNF4a (Gautier-Stein et al., 2005;
Schmidt et al., 2010), with which they are major sensors of
the metabolic state of hepatocytes.
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Currently, major objectives of the PXE research field are to
understand the pathomechanism of the disease and to
develop potential treatments of the various PXE symptoms
and PXE-associated phenotypes. Our results reported here
and in our previous report (de Boussac et al., 2010) both
point toward a potential unique role of ABCC6 among the
other ABC transporters in the metabolic processes of the cell.
This might indicate that the severity of PXE or various PXE-
related phenotypes is directly linked to the metabolic status of
the patients, potentially explaining the great variation of the
clinical phenotype even within the same family (Varadi et al.,
2011). This idea might serve as a basis of paradigm shift after
the recently disproved hypothesis on the role of ABCC6 in
vitamin K metabolism (Borst et al., 2008; Fulop et al., 2011)
and help to decipher the pathomechanism of the disease.
Finally, our results contribute to the development of
treatments of PXE and PXE-related conditions as well. Indeed,
the better understanding of the transcriptional regulation of
ABCC6 might contribute to the success of the recently
proposed allele-specific therapy of PXE caused by missense
mutations, when the protein is mislocalized but is still active
(Le Saux et al., 2011). In such a case, inducing the expression
of the gene and helping by chemical chaperones the proper
targeting of the protein might cure the disease. In conclusion,
our results may open new perspectives for targeting research
and development for the treatment of PXE, PXE-like, and
ABCC6 mutation carrier state–associated phenotypes by
focusing on the induction of ABCC6 expression as a new
therapeutic target.
MATERIALS AND METHODS
Cell culture
Cell lines were obtained from ATCC (Manassas, VA) and cultured
according to the manufacturer’s instructions. More specifically, HepG2
human hepatoma cell line was cultured in advanced MEM supple-
mented with 10% fetal bovine serum, 2mM glutamine, 100Uml1
penicillin, and 100mgml1 streptomycin. HeLa and HEK293 cells
were cultured in RPMI supplemented with 10% fetal bovine serum,
2mM glutamine, 100Uml1 penicillin, and 100 mgml1 streptomy-
cin. Caco-2 cells were cultured in advanced MEM supplemented
with 20% fetal bovine serum, glutamine, and antibiotics similar to
the other cell lines until reaching confluency (D0) and 14 more days
as described previously (D14) (Ribiczey et al., 2007). Postconfluent
Caco-2 cell cultures were refed by renewal of medium every second day.
DNase I hypersensitivity assay
A total of 6 106 cells were collected and resuspended in 100ml of
buffer C (11mM K-phosphate, pH 7.4, 108mM KCl, 22mM NaCl,
1mM MgCl2, 1mM DTT, and 1mM ATP) at 4 1C, and were then
treated with DNase I for 3minutes on ice. The DNase I digestion was
stopped by the addition of 2.5ml of lysis buffer (50mM Tris-HCl, pH
8, 20mM EDTA, and 1% SDS), followed by phenol extraction of the
genomic DNA.
Southern blot
Twenty micrograms of DNase I–treated DNA was digested overnight
with BsmI or NspI as indicated in the text. A probe located between
þ 1,435 and þ 1,735bp (relative to the translation start site) was
used. Primers to amplify the probe were designed and tested for
specificity (as all primers used in this study) by BiSearch (Aranyi et al.,
2006). The probe was radiolabeled with the DecaLabel DNA Labeling
Kit (Fermentas, Vilnius, Lithuania) and used for the Southern blot
assay. The assay was performed according to standard protocols.
Hybridization was carried out in QuickHyb (Stratagene, Santa Clara,
CA) at 65 1C for 3 hours. Membranes were exposed to hyperfilm (GE
Health Care, Little Chalfont, UK) for 24–36hours at 80 1C.
Promoter construct transfections and luciferase assay
Luciferase reporter gene assays were performed as described
previously (de Boussac et al., 2010). C/EBPb and other transcription
factor expression plasmids were purchased from Origene Technol-
ogies (Rockville, MD). New reporter plasmid vectors containing the
ABCC6-PXE promoter sequences were constructed by PCR cloning.
Human genomic DNA was used as template for amplification of the
construct 332/þ 960, and then this construct was used as template
for the amplification of the others. The restriction sites (KpnI site for
forward primers and HindIII site for reverse primers) were added to
the 50 end of primers, and promoter sequences were amplified using
high-fidelity thermostable DNA polymerase (TaqPfu). PCR products
were cloned into the pGL3-basic vector (Promega, Madison, WI).
The constructs were sequenced to avoid using constructs that do not
match the ABCC6-PXE gene sequence.
Site-directed mutagenesis
Mutations of the potential C/EBPb-binding sites in the ABCC6
promoter were generated by a similar PCR-based method as in our
previous study (Ratajewski et al., 2008). C/EBPb consensus binding
site is TKNNGNAAK. Three putative sites are present in the first
intron of the gene. The sites between þ 539 and þ 547 (TAATA-
CAAC mutated to TAATTCCCC—mutations in bold) and between
þ 585 and þ 593 (GAAGGAAAC mutated to GAAGTACCC) are
degenarate, whereas the third site between þ 632 and þ 640
(TTGTGAAAC mutated to TTGTTACCC) is consensus. The intro-
duced mutation of C/EBPb sites was based on a previous report of
Hayashida et al. (Ratajewski et al., 2008; Hayashida et al., 2009).
The sequences of the mutated inserts were verified by automated
sequencing. In double and triple mutant constructs, the same
mutations were included. We used the same method to create a HS2
deletion construct.
ChIP assay
ChIP and quantification of the transcription factor–bound genomic
DNA fragment were performed as described previously (de Boussac
et al., 2010). The following antibodies were used: normal mouse
IgG (part of the EZ-ChIP kit, Merck KGaA, Darmstadt, Germany)
and anti-C/EBPb (E299, Abcam, Cambridge, UK). Results were
normalized to total extracted DNA amount in samples taken before
immunoprecipitation by the deltaCt method.
Bioinformatics
In silico analysis of the genomic sequence was performed using
the following web servers: P-Match http://gene-regulation.com/cgi-
bin/pub/programs/pmatch/bin/p-match.cgi; Matinspector http://www.
genomatix.de/cgi-bin/sessions/login.pl?s=ed1de7682d64bd03ebafe-
fad4b12b450; and TF-search http://www.cbrc.jp/research/db/
TFSEARCH.html.
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ABCC6 promoter regions from 13 different species were
identified and downloaded using the UCSC genome browser (Kent
et al., 2002) (http://genome.ucsc.edu/). Genomic sequences used are
as follows: Homo sapiens (GRCh37/hg19 assembly), Pan troglodytes
(CGSC 2.1/panTro2 assembly), Macaca mulatta (MGSC Merged 1.0/
rheMac2 assembly), Callithrix jacchus (WUGSC 3.2/calJac3 assem-
bly), Mus musculus (NCBI37/mm9 assembly), Rattus norvegicus
(Baylor 3.4/rn4 assembly), Cavia porcellus (Broad/cavPor3 assem-
bly), Oryctolagus cuniculus (Broad/oryCun2 assembly), Ailuropoda
melanoleuca (BGI-Shenzhen 1.0/ailMel1 assembly), Loxodonta
africana (Broad/loxAfr3 assembly), Pongo pygmaeus abelii (WUGSC
2.0.2/ponAbe2 assembly), Bos Taurus (Baylor 4.0/bosTau4 assem-
bly), and Gallus gallus (WUGSC 2.1/galGal3 assembly). Multiple
sequence alignment was performed using the DIALIGN program
with default parameters (Morgenstern, 2004).
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